Furthermore, Ses treatment downregulated the protein expression of NLRC4, cleaved-caspase 1 and cleaved-IL-1β, effectively inhibiting inflammasome formation in the liver tissue of NASH mice and the PA-treated primary hepatocytes. This evidence concerns the gene NLRC4 and metabolic dysfunction-associated steatohepatitis.